| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 41899 |
Unlisted procedure, dentoalveolar structures |
494 |
489 |
$156K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
185 |
184 |
$74K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
479 |
466 |
$62K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
1,036 |
931 |
$44K |
| 42820 |
Tonsillectomy and adenoidectomy; younger than age 12 |
13 |
13 |
$41K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
525 |
450 |
$34K |
| 80053 |
Comprehensive metabolic panel |
5,394 |
4,581 |
$33K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
1,267 |
325 |
$32K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
6,108 |
4,773 |
$28K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
660 |
193 |
$21K |
| 36415 |
Collection of venous blood by venipuncture |
7,736 |
6,061 |
$17K |
| 70450 |
Computed tomography, head or brain; without contrast material |
348 |
334 |
$14K |
| 95810 |
Polysomnography; sleep staging with 4 or more additional parameters |
12 |
12 |
$14K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,136 |
1,085 |
$13K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
24 |
24 |
$12K |
| 71046 |
Radiologic examination, chest; 2 views |
690 |
662 |
$9K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
177 |
150 |
$8K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
392 |
109 |
$7K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
97 |
88 |
$7K |
| 81001 |
|
2,661 |
2,390 |
$7K |
| 81025 |
|
737 |
693 |
$7K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
83 |
79 |
$6K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
116 |
111 |
$5K |
| 71045 |
Radiologic examination, chest; single view |
598 |
556 |
$5K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
1,561 |
1,337 |
$4K |
| 85027 |
|
977 |
848 |
$4K |
| 84484 |
|
583 |
484 |
$4K |
| J2704 |
Injection, propofol, 10 mg |
1,308 |
1,252 |
$3K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
73 |
68 |
$3K |
| 83690 |
|
544 |
492 |
$3K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
526 |
478 |
$3K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
52 |
51 |
$3K |
| 82247 |
|
448 |
233 |
$2K |
| 74018 |
|
191 |
187 |
$2K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
1,122 |
991 |
$2K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
406 |
363 |
$2K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
87 |
87 |
$2K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,917 |
1,822 |
$2K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
468 |
401 |
$2K |
| 84439 |
|
249 |
244 |
$2K |
| 80061 |
Lipid panel |
275 |
263 |
$2K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
69 |
63 |
$1K |
| 84702 |
|
107 |
94 |
$1K |
| 80306 |
|
114 |
109 |
$1K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,806 |
1,660 |
$1K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,002 |
1,742 |
$1K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
3,209 |
2,014 |
$1K |
| 85378 |
|
166 |
161 |
$989.51 |
| 83735 |
|
268 |
223 |
$935.33 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
420 |
388 |
$900.08 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
599 |
529 |
$805.53 |
| 96361 |
Intravenous infusion, hydration; each additional hour |
37 |
25 |
$784.76 |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
16 |
16 |
$747.45 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
186 |
176 |
$744.93 |
| J2175 |
Injection, meperidine hydrochloride, per 100 mg |
193 |
180 |
$720.67 |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
32 |
32 |
$655.34 |
| 97161 |
|
12 |
12 |
$652.75 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
894 |
846 |
$636.32 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
1,456 |
1,379 |
$610.61 |
| 73630 |
|
42 |
39 |
$559.89 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
14 |
12 |
$411.92 |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
28 |
27 |
$372.84 |
| 86140 |
|
91 |
76 |
$370.34 |
| 86756 |
|
26 |
25 |
$365.90 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
19 |
13 |
$322.34 |
| 85610 |
|
103 |
91 |
$318.08 |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
54 |
12 |
$281.92 |
| 85651 |
|
108 |
88 |
$267.06 |
| 73130 |
|
14 |
13 |
$255.04 |
| 73610 |
|
13 |
12 |
$196.13 |
| 82248 |
|
45 |
44 |
$186.82 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
59 |
48 |
$173.70 |
| 82728 |
|
14 |
12 |
$106.03 |
| 86900 |
|
27 |
25 |
$89.87 |
| 87070 |
|
13 |
12 |
$89.48 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
839 |
804 |
$79.43 |
| 87040 |
|
17 |
12 |
$73.29 |
| 86901 |
|
14 |
12 |
$58.47 |
| J2060 |
Injection, lorazepam, 2 mg |
29 |
26 |
$14.15 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
136 |
133 |
$6.15 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
12 |
12 |
$5.30 |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
42 |
41 |
$5.18 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
27 |
25 |
$2.94 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
26 |
26 |
$1.24 |
| A9270 |
Non-covered item or service |
174 |
106 |
$0.00 |